寡转移前列腺癌的治疗进展  

Progress on the treatment of oligometastatic prostate cancer

作　　者：李明焕[1] 边家盛[2] Li Minghuan;Bian Jiasheng(Department of Radiation Oncology,Shandong Cancer Hospital and Institute,Affiliated Cancer Hospital of Shandong First Medical University,Jinan 250117,China;Department of Urology,Shandong Cancer Hospital and Institute,Affiliated Cancer Hospital of Shandong First Medical University,Jinan 250117,China)

机构地区：[1]山东省肿瘤防治研究院山东第一医科大学附属肿瘤医院放疗科,济南250117 [2]山东省肿瘤防治研究院山东第一医科大学附属肿瘤医院泌尿外科,济南250117

出　　处：《中华泌尿外科杂志》2024年第7期559-562,共4页Chinese Journal of Urology

基　　金：国家自然科学基金面上项目(82172677)。

摘　　要：基于精准诊断的寡转移前列腺癌患者应给予积极治疗。全身治疗、前列腺局部治疗以及转移灶的治疗都应争取最大的肿瘤控制并减少治疗不良反应。目前全身治疗的最佳药物组合和持续时间尚不明确,推荐在雄激素剥夺治疗基础上联合新一代抗雄药物;大多数专家推荐内分泌治疗持续时间为18~36个月。原发灶的局部治疗包括手术和放疗,其安全性和有效性已得到临床证实。对转移灶进行立体定向放射治疗能够提供安全、可靠的局部控制。总之,用高效低毒的治疗手段最大程度杀灭所有可见活性病灶,可能为患者带来生存获益。本文对激素敏感性寡转移前列腺癌的治疗进展进行综述,以期为临床诊治提供帮助。Patients with oligometastatic prostate cancer based on accurate diagnosis should be given active treatment.We should optimize the benefit through tailored approaches encompassing systemic treatment,local therapy,and metastasis-directed therapy.The optimal combination and duration of systemic treatment are currently undefined.Combining new hormonal agents with androgen deprivation therapy is recommended.Most experts advocate a duration of hormonal therapy ranging from 18 to 36 months.Local therapy for the primary lesion,surgery or radiotherapy,has been clinically validated for its feasibility and effectiveness in oligometastatic prostate cancer patients.Stereotactic ablative radiation therapy for metastatic lesions ensures safe and reliable local control.In summary,maximal eradication of all visible active lesions may confer a survival benefit to these patients.We provide a comprehensive review for the treatment of oligometastatic hormone-sensitive prostate cancer,aiming to contribute insights for clinical diagnosis and treatment.

关 键 词：前列腺肿瘤 癌 寡转移 全身治疗 局部治疗 

分 类 号：R737.25[医药卫生—肿瘤]